DexCom, Inc. (DXCM)

In the past six months, DexCom's stock price has been impacted by several events. A securities class action lawsuit was filed alleging misrepresentation of the accuracy and reliability of its G6 and G7 CGM devices. The FDA published a warning letter stating that the G6 and G7 CGM systems were "adulterated" due to unapproved modifications. DexCom reported strong fourth-quarter and fiscal year 2025 financial results. Evercore upgraded DexCom from "in-line" to "outperform" with a $90.00 price target in March 2026. TD Cowen reiterated a "Buy" rating with an $84.00 price target in April 2026. Rick Osterloh was appointed to the Board of Directors, effective February 26, 2026. While the stock price has been relatively stable in the past three months, it underperformed the broader U.S. market over the past year, though it exceeded the U.S. Medical Equipment industry.

Explicit details regarding the seasonality of demand for DexCom's products and services are not readily available. The company's business model suggests a recurring revenue stream rather than strong seasonal fluctuations in product demand. DexCom's growth is driven by factors such as increasing diabetes prevalence, broader CGM adoption, expanding Medicare coverage, and new product launches, indicating a more consistent demand influenced by market expansion and product innovation rather than specific seasonal patterns.

DexCom, Inc. is a medical device company specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes. The company designs, develops, and commercializes glucose monitoring systems. Its major products include the Dexcom G6 CGM System, which continuously tracks glucose levels and integrates with other diabetes management technologies; the Dexcom G7 CGM System, a smaller and more user-friendly next-generation CGM system; Dexcom Stelo, the first over-the-counter glucose biosensor cleared by the FDA; Dexcom ONE, a product utilizing G6 hardware with a simplified feature set; Dexcom Share, a remote monitoring system; and Dexcom Real-Time API, an application programming interface for real-time data access.

DexCom, Inc. is headquartered in San Diego, California, USA, which also serves as its global headquarters and R&D center. The company has manufacturing facilities in Mesa, Arizona, USA; Batu Kawan, Malaysia; and Athenry, County Galway, Ireland. DexCom operates internationally, with a significant presence in North America and Europe. In fiscal year 2023, the United States generated the highest percentage of its total revenue. The company focuses on expanding its reach into new international markets and broadening reimbursement coverage globally.

DexCom has established itself as a leader in the continuous glucose monitoring market. However, its brand reputation in the past year has been affected by the FDA Warning Letter stating that DexCom's G6 and G7 CGM systems were "adulterated" due to unapproved modifications. The filing of a class action lawsuit alleging that the company misrepresented the accuracy and reliability of its G6 and G7 devices also impacted the brand reputation.

DexCom, Inc. has a high concentration of institutional ownership, with approximately 97.75% to 98.5% of its stock held by institutions. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Insider ownership is less than 1%, with recent filings indicating mostly selling activity by executives and directors, alongside a smaller number of share additions.